---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-104545"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T18:12:14.339062+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa Q2 net loss narrows to $12.3M on $23.2M collaboration revenue; cash runway to 2028

## Summary
- Collaboration revenue $23.2M (vs $4.7M YoY) from Novartis license; net loss improved to $12.3M from $30.3M.
- R&D $30.7M, G&A $8.1M; cash $295.5M (down $35.5M from Q1), expected to fund into 2028.
- Phase 1 of NEK7-directed MGD MRT-8102 dosed; initial data expected H1 2026 for inflammatory diseases.
- MRT-6160 advancing toward multiple Phase 2 studies with Novartis; potential milestones up to $2.1B.

## SEC filing metadata
- accession: 0000950170-25-104545
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000095017025104545/0000950170-25-104545-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000095017025104545/glue-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-104545
- JSON: https://secwatch.observer/filing/0000950170-25-104545.json
- Plain text: https://secwatch.observer/filing/0000950170-25-104545.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.